Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	1

Complete if Known				
Application Number	10/559,982			
Filing Date	February 2, 2006			
First Named Inventor	Ruggero Fariello			
Group Art Unit	1617			
Examiner Name	Sahar JAVANMARD			
Confirmation No.	6583			
Attorney Docket No.	373987-011US (102895)			

U.S. PUBLISHED DOCUMENTS						
Examiner Initials*	Cite No.1	U.S. Public Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
	A1					

	FOREIGN PATENT DOCUMENTS								
Examiner	Cite	For	eign Patent Docu	ment	Date of		Transla	tion ²	
Initials*	No. 1	Office	Number	Kind Code (if known)	Publication of Cited Document MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Yes	No	
	B1								

Examin Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate),		Translation ²	
er Initials*	No. 1 title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		Yes	No
	C113	Caccia et al., "Safinamide: from molecular targets to a new anti-Parkinson drug," Neurology 67 (suppl. 2):S18-S23 (2006)		
	C114	Meshram et al., "Safinamide as add-on to levodopa improves motor function without worsening dyskinesia in patients with mid-late Parkinson's disease," Poster 359, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010.		
	C115	Rascol et al., "A 2-year, multicenter, placebo-controlled, double-blind, parallel group study of the effect of riluzole on Parkinson's disease progression," Movement Disorders, 17 (Suppl. 5), S29 (2002)		
	C116	Borgohain et al., "Effect of safinamide on depressive symptoms in patients with mid- late stage Parkinson's disease," Poster 324, Movement Disorder Society 14th International Congress, Buenos Aires, Argentina, 13-17 June 2010 ("Borgohain")		

Examiner Signature		Date Considered	
	if reference considered, whether or not citation is in conformance with MPEP 609. Do sm with next communication to applicant.	raw line through citation is	not in conformance and not considered.